Emerging Evidence for MicroRNAs as Regulators of Cancer Stem Cells

Por Sethi, Aisha, Sholl, Lynette M.
Publicado em 2011

Anti–PD-1–Related Pneumonitis during Cancer Immunotherapy

Por Nishino, Mizuki, Sholl, Lynette M., Hodi, F. Stephen
Publicado no N Engl J Med (2015)

Thymic measurements in pathologically proven normal thymus and thymic hyperplasia: Intra- and interobserver variability

Por Araki, Tetsuro, Sholl, Lynette M., Gerbaudo, Victor H., Hatabu, Hiroto, Nishino, Mizuki
Publicado em 2014

Imaging Characteristics of Pathologically Proven Thymic Hyperplasia: Identifying Features That Can Differentiate True From Lymphoid Hyperplasia

Por Araki, Tetsuro, Sholl, Lynette M., Gerbaudo, Victor H., Hatabu, Hiroto, Nishino, Mizuki
Publicado em 2014

SOX2 PROTEIN EXPRESSION IS AN INDEPENDENT POOR PROGNOSTIC INDICATOR IN STAGE I LUNG ADENOCARCINOMA

Por Sholl, Lynette M., Barletta, Justine A., Yeap, Beow Y., Chirieac, Lucian R., Hornick, Jason L.
Publicado em 2010

Brief report: Clinical implications of variant ALK FISH rearrangement patterns

Por Gao, Xin, Sholl, Lynette M., Nishino, Mizuki, Heng, Jennifer, Jänne, Pasi A., Oxnard, Geoffrey R.
Publicado no J Thorac Oncol (2015)

ROS1 Immunohistochemistry for Detection of ROS1-Rearranged Lung Adenocarcinomas

Por Sholl, Lynette M., Sun, Heather, Butaney, Mohit, Zhang, Chengsheng, Lee, Charles, Jänne, Pasi A., Rodig, Scott J.
Publicado em 2013

Primary Pulmonary NUT-Midline Carcinoma: Clinical, Radiographic, and Pathologic Characterization

Por Sholl, Lynette M., Nishino, Mizuki, Pokharel, Saraswati, Mino-Kenudson, Mari, French, Christopher A., Janne, Pasi A., Lathan, Christopher
Publicado no J Thorac Oncol (2015)

Pathologic Characteristics of NUT Midline Carcinoma Arising in the Mediastinum

Por Evans, Andrew G., French, Christopher A., Cameron, Michael J., Fletcher, Christopher D., Jackman, David M., Lathan, Christopher S., Sholl, Lynette M.
Publicado em 2012

Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab

Por Nishino, Mizuki, Cryer, Sarah K., Okajima, Yuka, Sholl, Lynette M., Hatabu, Hiroto, Rabin, Michael S., Jackman, David M., Johnson, Bruce E.
Publicado em 2012

Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK- Rearranged Lung Adenocarcinomas

Por Sholl, Lynette M., Weremowicz, Stanislawa, Gray, Stacy W., Wong, Kwok-Kin, Chirieac, Lucian R., Lindeman, Neal I., Hornick, Jason L.
Publicado em 2013

An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and ALK FISH and between Evaluator...

Por Wynes, Murry W., Sholl, Lynette M., Dietel, Manfred, Schuuring, Ed, Tsao, Ming S., Yatabe, Yasushi, Tubbs, Raymond R., Hirsch, Fred R.
Publicado em 2014

Clinical and molecular characteristics of NF1 mutant lung cancer

Por Redig, Amanda J., Capelletti, Marzia, Dahlberg, Suzanne E., Sholl, Lynette M., Mach, Stacy, Fontes, Caitlin, Shi, Yunling, Chalasani, Poornima, Jänne, Pasi A.
Publicado no Clin Cancer Res (2016)

EGFR Mutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry

Por Sholl, Lynette M., Xiao, Yun, Joshi, Victoria, Yeap, Beow Y., Cioffredi, Leigh-Anne, Jackman, David M., Lee, Charles, Jänne, Pasi A., Lindeman, Neal I.
Publicado em 2010

Clinical, pathological and biological features associated with BRAF mutations in non-small cell lung cancer

Por Cardarella, Stephanie, Ogino, Atsuko, Nishino, Mizuki, Butaney, Mohit, Shen, Jeanne, Lydon, Christine, Yeap, Beow Y., Sholl, Lynette M., Johnson, Bruce E., Jänne, Pasi A.
Publicado em 2013

Treatment-related Toxicities in a Phase II Trial of Dasatinib in Patients with Squamous Cell Carcinoma of the Lung: A Brief Report

Por Brunner, Andrew M., Costa, Daniel B., Heist, Rebecca S., Garcia, Elizabeth, Lindeman, Neal I., Sholl, Lynette M., Oxnard, Geoffrey R., Johnson, Bruce E., Hammerman, Peter S.
Publicado em 2013

Identification of existing drugs that effectively target NTRK1- and ROS1-rearrangements in lung cancer

Por Chong, Curtis R., Bahcall, Magda, Capelletti, Marzia, Kosaka, Takayuki, Ercan, Dalia, Sim, Taebo, Sholl, Lynette M., Nishino, Mizuki, Johnson, Bruce E., Gray, Nathanael S., Jänne, Pasi A.
Publicado no Clin Cancer Res (2016)

Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression

Por Howitt, Brooke E., Strickland, Kyle C., Sholl, Lynette M., Rodig, Scott, Ritterhouse, Lauren L., Chowdhury, Dipanjan, D'Andrea, Alan D., Matulonis, Ursula A., Konstantinopoulos, Panagiotis A.
Publicado no Oncoimmunology (2017)

Chemotherapy and irradiation for locally advanced and metastatic pulmonary carcinoid tumors

Por Chong, Curtis R., Wirth, Lori J., Nishino, Mizuki, Chen, Aileen B., Sholl, Lynette M., Kulke, Matthew H., McNamee, Ciaran J., Jänne, Pasi A., Johnson, Bruce E.
Publicado no Lung Cancer (2014)

PD-1 inhibitor-related pneumonitis in advanced cancer patients: Radiographic patterns and clinical course

Por Nishino, Mizuki, Ramaiya, Nikhil H., Awad, Mark M., Sholl, Lynette M., Maattala, Jennifer A., Taibi, Myriam, Hatabu, Hiroto, Ott, Patrick A., Armand, Philippe F, Hodi, F. Stephen
Publicado no Clin Cancer Res (2016)